Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Cash from Investing Activities (2016 - 2025)

Dare Bioscience (DARE) has disclosed Cash from Investing Activities for 11 consecutive years, with -$174702.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities fell 161.88% year-over-year to -$174702.0, compared with a TTM value of -$741486.0 through Sep 2025, down 20.07%, and an annual FY2024 reading of -$573046.0, up 8.96% over the prior year.
  • Cash from Investing Activities was -$174702.0 for Q3 2025 at Dare Bioscience, down from $153396.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $282325.0 in Q3 2024 and bottomed at -$607331.0 in Q4 2023.
  • Average Cash from Investing Activities over 5 years is -$104193.3, with a median of -$18311.5 recorded in 2021.
  • The sharpest move saw Cash from Investing Activities crashed 22418.76% in 2023, then surged 1377.55% in 2024.
  • Year by year, Cash from Investing Activities stood at -$14524.0 in 2021, then surged by 81.43% to -$2697.0 in 2022, then plummeted by 22418.76% to -$607331.0 in 2023, then rose by 7.32% to -$562849.0 in 2024, then soared by 68.96% to -$174702.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for DARE at -$174702.0 in Q3 2025, $153396.0 in Q2 2025, and -$157331.0 in Q1 2025.